STAGE IVB PROSTATE CANCER AJCC V8

This early-phase trial tested whether adding a chemotherapy drug (decitabine/cedazuridine) to the standard drug enzalutamide could help men with metastatic castration-resistant prostate cancer whose cancer had stopped responding to enzalutamide alone. Only 8 men were enrolled bef…

This phase 2 trial tested the drug erdafitinib in 11 men with castration-resistant prostate cancer that had spread to the bone. The study aimed to see if erdafitinib could slow cancer growth by blocking certain enzymes. Researchers also collected blood and bone marrow samples to …

This study tested a combination of two drugs, apalutamide and abiraterone, along with prednisone, in men whose prostate cancer had spread and stopped responding to standard hormone therapy. The goal was to see if this combination could slow cancer growth. Only 7 men took part bef…

This early-phase study tested whether adding the immunotherapy drug vudalimab (XmAb20717) to standard hormone therapy or chemotherapy could help men with prostate cancer that has spread. Only 4 men took part before the study was stopped. The main goals were to check safety and se…

This study tested a new imaging agent called 68Ga-PSMA-11 to see if it could give clearer pictures of where prostate cancer has spread in men with advanced, treatment-resistant disease. The goal was to help doctors better understand the location of tumors. The study was terminate…

This study tested a radioactive drug called Sn-117m-DTPA to see if it could reduce bone pain in men with prostate cancer that had spread to their bones and no longer responded to hormone therapy. Only one person enrolled before the study was stopped. The goal was to measure pain …

This study offered genetic testing to men whose prostate cancer has spread to other parts of the body. Participants provided saliva samples to check for inherited mutations in about 30 cancer-risk genes. The goal was to understand how often these mutations occur and how men feel …